publication

20 Jun 2024 BEAT® Antibody Engineering Platform Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach Peltret M. et al. Journal…

12 Dec 2022 ISB 1442 Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma Jiang T.…

13 Apr 2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al. American Association for…